Please assess the completion status of the following clinical trial:

Trial Title: Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* eGFR \> 60 mL/min/1.73 mq (for the patients without renal failure)~* eGFR 10-60 mL/min/1.73 mq (for the patients with renal failure)~Exclusion Criteria:~* Type 1 diabetes~* Hypersensitivity to Linagliptin or excipients~* Intolerance to other DPP-4 inhibitors~* Terminal renal failure (eGFR \< 10 mL/min/1.73 mq)~* Use of GLP-1 analogs or other DPP-4 inhibitors~* Recent (within 1 month) trauma or surgery or acute diseases~* Any acute or chronic inflammatory condition~* Immunosuppression or organ transplantation~* Pregnancy or lactation~* Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): Linagliptin 5 mg tablets daily for 4 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets 1 daily for 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).